+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years



High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years



Blood 113(5): 995-1001



Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT. Conditioning was performed with total body irradiation (TBI) and cyclophosphamide. The 9-year overall survival (OS) was similar in the HDT and conventional chemotherapy groups (76% and 80%, respectively). The 9-year progression-free survival (PFS) was higher in the ASCT than the chemotherapy group (64% vs 39%; P = .004). A PFS plateau was observed in the HDT group after 7 years. On multivariate analysis, OS and PFS were independently affected by the per-formance status score, the number of nodal areas involved, and the treatment group. Secondary malignancies were more frequent in the HDT than in the chemotherapy group (6 secondary myelodysplastic syndrome/acute myeloid leukemia and 6 second solid tumor cancers vs 1 acute myeloid leukemia, P = .01). The occurrence of a PFS plateau suggests that a subgroup of patients might have their FL cured by ASCT. However, the increased rate of secondary malignancies may discourage the use of purged ASCT in combination with TBI as first-line treatment for FL. This trial has been registered with ClinicalTrials.gov under identifier NCT00696735.

(PDF emailed within 0-6 h: $19.90)

Accession: 053544642

Download citation: RISBibTeXText

PMID: 18955565

DOI: 10.1182/blood-2008-05-160200


Related references

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10): 3817-3823, 2005

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study ofthe GOELAMS group. Bone Marrow Transplantation 38(6): 417-420, 2006

Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden Final results of the randomized GOELAMS 064 Trial. Blood 102(11): 246a, November 16, 2003

Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study. Bone Marrow Transplantation 26(9): 971-977, November 1, 2000

The role of high-dose therapy followed by autologous purged stem cell transplantation in previously untreated patients with advanced follicular lymphoma. Current Hematology Reports 4(4): 249-251, 2005

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer 113(12): 3323-3330, 2008

Frontline High-Dose Chemotherapy with Autologous Stem Cell Transplantation vs Standard CHOP Regimen for Patients with Non IPI High-Risk Intermediate or High-Grade Lymphomas Final Results of a Randomized Trial by the GOELAMS. Blood 100(11): Abstract No 675, November 16, 2002

Value of autologous stem cell transplantation in first line therapy of follicular lymphoma with high tumor burden First results of the randomized GOELAMS 064 trial. Blood 98(11 Part 1): 861a, November 16, 2001

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108(8): 2540-2544, 2006

High-dose therapy with purged autologous stem cell transplantation as firstline therapy for follicular lymphoma. Blood 96(11 Part 2): 376b, November 16, 2000

Treatment of Follicular and Mantle Cell Lymphoma with Rituximab after High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation A Multicenter Phase II Study. Blood 100(11): Abstract No 2532, November 16, 2002

High dose chemotherapy (HDCT) plus autologous stem cell transplantation (ASCT) in multiple sclerosis (MS) patients: Follow-up results of a prospective multicenter study. 2007

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Annals of Oncology 15(11): 1691-1698, 2004

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet. Oncology 18(8): 1076-1088, 2017

High dose chemotherapy with autologous stem cell transplantation in high grade NHL Results of a randomized multicenter study. Annals of Hematology 77(SUPPL 2): S11, 1998